Area of research
Cancer Research · Biochemistry
Research interest
Research interests include Amiloride, Chemistry, Plasminogen activator, Pharmacology, Urokinase receptor, and Urokinase.
PAI-1 deficiency drives pulmonary vascular smooth muscle remodeling and pulmonary hypertension
Ion Transport and Inhibitor Binding by Human NHE1: Insights from Molecular Dynamics Simulations and Free Energy Calculations
A dual-targeting succinate dehydrogenase and F1Fo-ATP synthase inhibitor rapidly sterilizes replicating and non-replicating Mycobacterium tuberculosis
Automated Patch Clamp Screening of Amiloride and 5- <i>N</i> , <i>N</i> -Hexamethyleneamiloride Analogs Identifies 6-Iodoamiloride as a Potent Acid-Sensing Ion Channel Inhibitor
Antifungal activity of 6-substituted amiloride and hexamethylene amiloride (HMA) analogs
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)
The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets
An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis
Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity
6-Furopyridine Hexamethylene Amiloride Is a Non-Selective P2X7 Receptor Antagonist
Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors
Systematic evaluation of structure–property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride
Roles of the Na+/H+ Exchanger Isoform 1 and Urokinase in Prostate Cancer Cell Migration and Invasion
Novel Amiloride Derivatives That Inhibit Bacterial Motility across Multiple Strains and Stator Types
Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA)
Urokinase plasminogen activator as an anti-metastasis target: Inhibitor design principles, recent amiloride derivatives and issues with human/mouse species selectivity
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer
The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets